Share on StockTwits

Boston Scientific (NYSE:BSX) is scheduled to issue its Q114 quarterly earnings data on Tuesday, April 29th. Analysts expect the company to announce earnings of $0.18 per share and revenue of $1.80 billion for the quarter. Boston Scientific has set its Q1 guidance at $0.16-0.18 EPS and its FY14 guidance at $0.75-0.80 EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Tuesday, February 4th. The company reported $0.21 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.13 by $0.08. The company had revenue of $1.84 billion for the quarter, compared to the consensus estimate of $1.83 billion. During the same quarter in the prior year, the company posted $0.18 earnings per share. The company’s quarterly revenue was up .9% on a year-over-year basis. On average, analysts expect Boston Scientific to post $0.78 EPS for the current fiscal year and $0.88 EPS for the next fiscal year.

Boston Scientific (NYSE:BSX) opened at 13.38 on Monday. Boston Scientific has a 52 week low of $7.41 and a 52 week high of $14.08. The stock’s 50-day moving average is $13.29 and its 200-day moving average is $12.61. The company’s market cap is $17.718 billion.

Several analysts have recently commented on the stock. Analysts at RBC Capital raised their price target on shares of Boston Scientific from $14.00 to $15.00 in a research note on Wednesday, April 23rd. They now have an “outperform” rating on the stock. On the ratings front, analysts at Ned Davis Research upgraded shares of Boston Scientific from a “sell” rating to a “neutral” rating in a research note on Monday, April 21st. Finally, analysts at Bank of America upgraded shares of Boston Scientific from a “neutral” rating to a “buy” rating in a research note on Monday, April 14th. They now have a $16.00 price target on the stock, up previously from $15.00. They noted that the move was a valuation call. Nine research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $13.10.

In other Boston Scientific news, EVP Michael Phalen unloaded 13,500 shares of the company’s stock on the open market in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $13.25, for a total value of $178,875.00. Following the transaction, the executive vice president now directly owns 127,486 shares in the company, valued at approximately $1,689,190. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.